Champions Oncology Launches Comprehensive Radiopharmaceutical Platform

Champions Oncology, a leader in translational oncology research, announced the commercial launch of its new radiopharmaceutical services platform. This development follows the expansion of their radioactive materials license and the successful screening of over thirty PDX models. This advancement allows for integrated workflows, combining various studies using an extensive range of isotopes.

The platform is distinguished by its robust bank of patient-derived xenograft (PDX) tumor models, offering drug developers the ability to assess radiolabeled agents effectively. The updated license now supports ten key isotopes, facilitating diverse study designs such as radioligand therapy and antibody radionuclide conjugates.

The initiative aims to accelerate critical drug development decisions with data reflecting authentic tumor biology, supporting biopharma partners in preclinical evaluations.